Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer

Anticancer Res. 2021 Nov;41(11):5793-5802. doi: 10.21873/anticanres.15396.

Abstract

Background/aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC).

Patients and methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors. The prescribed radiation dose for the gross tumor and the elective nodal area was 69 Gy in 30 fractions and 51 Gy in 30 fractions, respectively.

Results: Radiation pneumonitis developed in 38 patients (76%, 38/50), and grade ≥2 radiation pneumonitis developed in 11 patients (22%, 11/50). The percentage of lung volume that received a dose in excess of 5 Gy (V5), V10, V20, V30, and the mean lung dose (MLD) in the bilateral and ipsilateral lung were significantly associated with the development of grade ≥2 radiation pneumonitis.

Conclusion: The incidence and degree of radiation pneumonitis are acceptable following treatment of NSCLC with VMAT.

Keywords: IMRT; Non-small cell lung cancer; VMAT; chemoradiotherapy; radiation pneumonitis.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Female
  • Humans
  • Incidence
  • Japan / epidemiology
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prospective Studies
  • Radiation Dosage
  • Radiation Pneumonitis / diagnosis
  • Radiation Pneumonitis / epidemiology*
  • Radiotherapy, Intensity-Modulated / adverse effects*
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome